Viking Therapeutics Faces Key Catalysts Ahead
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 48 minutes ago
0mins
Source: Fool
- Clinical Trial Progress: Viking Therapeutics' VK2735 is currently in phase 3 trials, with data expected next year; if it can replicate its strong phase 2 results, the stock could see significant appreciation, attracting more investor interest.
- Market Potential: With the anti-obesity drug market projected to grow rapidly over the next decade, Viking Therapeutics faces heightened market expectations, and despite an 8% decline in stock price this year, it is still viewed as a potential investment opportunity.
- Product Line Expansion: The company plans to initiate late-stage studies for an oral formulation of VK2735 by year-end, which could further strengthen its position in the competitive weight-loss drug market and enhance future revenue potential.
- Risks and Opportunities: While Viking Therapeutics' stock is seen as an attractive investment option, investors must be aware of potential risks, particularly setbacks in clinical trials, and it is advisable for risk-tolerant investors to consider initiating a small position.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VKTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VKTX
Wall Street analysts forecast VKTX stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 30.380
Low
70.00
Averages
97.00
High
125.00
Current: 30.380
Low
70.00
Averages
97.00
High
125.00
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Viking Therapeutics Phase 3 Study Progress
- Clinical Trial Progress: Viking Therapeutics' leading anti-obesity candidate VK2735 is currently in phase 3 studies, with data expected next year; if results are positive, the stock could significantly rise from its current price of $32.
- Market Outlook: Despite an 8% decline in stock price this year, Viking Therapeutics has the potential to carve out a niche in the rapidly growing anti-obesity market, especially with late-stage studies for its oral VK2735 formulation expected to start by year-end.
- Investment Risk Assessment: Although VK2735 showed strong results in phase 2 trials, the increasing competition in the anti-obesity sector means Viking Therapeutics must exceed market expectations in upcoming trials to ensure stock price appreciation.
- Investment Recommendation: For risk-tolerant investors, the current stock price may present an attractive entry point; however, conservative investors might want to explore other options due to potential volatility.
See More
Viking Therapeutics Faces Key Catalysts Ahead
- Clinical Trial Progress: Viking Therapeutics' VK2735 is currently in phase 3 trials, with data expected next year; if it can replicate its strong phase 2 results, the stock could see significant appreciation, attracting more investor interest.
- Market Potential: With the anti-obesity drug market projected to grow rapidly over the next decade, Viking Therapeutics faces heightened market expectations, and despite an 8% decline in stock price this year, it is still viewed as a potential investment opportunity.
- Product Line Expansion: The company plans to initiate late-stage studies for an oral formulation of VK2735 by year-end, which could further strengthen its position in the competitive weight-loss drug market and enhance future revenue potential.
- Risks and Opportunities: While Viking Therapeutics' stock is seen as an attractive investment option, investors must be aware of potential risks, particularly setbacks in clinical trials, and it is advisable for risk-tolerant investors to consider initiating a small position.
See More
Anti-Obesity Drug Market Faces Potential Disruption
- Market Dominance: Eli Lilly and Novo Nordisk dominate the U.S. obesity and diabetes treatment market with their GLP-1 drugs, creating a potential duopoly that presents opportunities for new entrants to challenge the status quo.
- Viking Therapeutics' Competitiveness: Viking Therapeutics' VK2735 shows promising early data in phase 2 trials, with participants losing up to 14.7% of their weight over 13 weeks, indicating its competitive edge in a market with limited share.
- Market Potential: If the anti-obesity drug market reaches $100 billion in the next decade, Viking only needs to capture 1% of the market to significantly boost its valuation, highlighting its potential threat to the revenues of Lilly and Novo Nordisk.
- Clinical Trial Progress: VK2735's phase 3 trials have just completed enrollment, with results expected by 2027; if these results confirm earlier data, it will greatly enhance its competitive position in the obesity drug market.
See More
Viking Therapeutics Aims to Disrupt Obesity Drug Market
- Competitive Candidate: Viking Therapeutics' VK2735 demonstrated strong early data in two phase 2 trials, with participants losing 14.7% and 12.2% of their weight over 13 weeks, indicating its potential to compete with Eli Lilly and Novo Nordisk in the obesity drug market.
- Market Share Opportunity: With a market cap of just $3.5 billion, capturing even 1% of the projected $100 billion weight-loss drug market could significantly elevate Viking's valuation, providing substantial returns for shareholders.
- Clinical Trial Progress: The phase 3 trials for the injectable formulation of VK2735 completed enrollment earlier this year, with top-line data not expected until 2027, while the oral formulation's phase 3 trial is anticipated to begin by the end of this year.
- Industry Competitive Landscape: Although VK2735 shows competitive potential in the short term, it must prove its long-term efficacy against late-stage candidates like Eli Lilly's retatrutide and Novo Nordisk's CagriSema to secure a foothold in the market.
See More
Teads and Corning See Surge in Options Trading Volume
- Teads Options Volume: Teads Holding Co experienced options trading volume of 1,934 contracts, equivalent to approximately 193,400 shares, representing about 65.3% of its average daily trading volume of 296,010 shares over the past month, indicating market interest in its future performance.
- High Strike Call Options: Specifically, the $2.50 strike call option for Teads saw 1,030 contracts traded today, representing around 103,000 underlying shares, reflecting investor expectations for the stock's upward movement before expiration on July 17, 2026.
- Corning Options Activity: Corning Inc recorded options trading volume of 82,742 contracts, translating to approximately 8.3 million shares, which is about 65.1% of its average daily trading volume of 12.7 million shares over the past month, showcasing strong market interest in its stock.
- Corning High Strike Call Options: For Corning, the $300 strike call option traded 4,704 contracts today, representing approximately 470,400 underlying shares, indicating investor optimism regarding potential price increases before the option's expiration on July 17, 2026.
See More
Amazon and Costco: Top Picks for Long-Term Investment
- Amazon's Market Advantage: Amazon (AMZN) holds a massive market share in e-commerce and cloud computing, with a market cap of $2.6 trillion, and is poised for future growth driven by its strong global network and Prime membership service amidst the AI boom.
- AWS Growth Potential: Amazon Web Services (AWS), the world's largest cloud service provider, boasts an annual revenue run rate of $150 billion, benefiting from a surge in AI projects, which further solidifies Amazon's profitability and market position.
- Costco's Business Model: Costco (COST) is renowned for its membership-based low-price strategy, with a market cap of $422 billion and a renewal rate exceeding 92% in the U.S. and Canada, providing visibility for future profits.
- Expansion Plans and Profitability: With 928 stores globally and plans to open over 30 new warehouses annually, Costco's high-margin membership fees ensure long-term profitability and competitive strength, despite low margins on product sales.
See More
Viking Therapeutics Phase 3 Study Progress
- Clinical Trial Progress: Viking Therapeutics' leading anti-obesity candidate VK2735 is currently in phase 3 studies, with data expected next year; if results are positive, the stock could significantly rise from its current price of $32.
- Market Outlook: Despite an 8% decline in stock price this year, Viking Therapeutics has the potential to carve out a niche in the rapidly growing anti-obesity market, especially with late-stage studies for its oral VK2735 formulation expected to start by year-end.
- Investment Risk Assessment: Although VK2735 showed strong results in phase 2 trials, the increasing competition in the anti-obesity sector means Viking Therapeutics must exceed market expectations in upcoming trials to ensure stock price appreciation.
- Investment Recommendation: For risk-tolerant investors, the current stock price may present an attractive entry point; however, conservative investors might want to explore other options due to potential volatility.
See More
Viking Therapeutics Faces Key Catalysts Ahead
- Clinical Trial Progress: Viking Therapeutics' VK2735 is currently in phase 3 trials, with data expected next year; if it can replicate its strong phase 2 results, the stock could see significant appreciation, attracting more investor interest.
- Market Potential: With the anti-obesity drug market projected to grow rapidly over the next decade, Viking Therapeutics faces heightened market expectations, and despite an 8% decline in stock price this year, it is still viewed as a potential investment opportunity.
- Product Line Expansion: The company plans to initiate late-stage studies for an oral formulation of VK2735 by year-end, which could further strengthen its position in the competitive weight-loss drug market and enhance future revenue potential.
- Risks and Opportunities: While Viking Therapeutics' stock is seen as an attractive investment option, investors must be aware of potential risks, particularly setbacks in clinical trials, and it is advisable for risk-tolerant investors to consider initiating a small position.
See More
Anti-Obesity Drug Market Faces Potential Disruption
- Market Dominance: Eli Lilly and Novo Nordisk dominate the U.S. obesity and diabetes treatment market with their GLP-1 drugs, creating a potential duopoly that presents opportunities for new entrants to challenge the status quo.
- Viking Therapeutics' Competitiveness: Viking Therapeutics' VK2735 shows promising early data in phase 2 trials, with participants losing up to 14.7% of their weight over 13 weeks, indicating its competitive edge in a market with limited share.
- Market Potential: If the anti-obesity drug market reaches $100 billion in the next decade, Viking only needs to capture 1% of the market to significantly boost its valuation, highlighting its potential threat to the revenues of Lilly and Novo Nordisk.
- Clinical Trial Progress: VK2735's phase 3 trials have just completed enrollment, with results expected by 2027; if these results confirm earlier data, it will greatly enhance its competitive position in the obesity drug market.
See More
Viking Therapeutics Aims to Disrupt Obesity Drug Market
- Competitive Candidate: Viking Therapeutics' VK2735 demonstrated strong early data in two phase 2 trials, with participants losing 14.7% and 12.2% of their weight over 13 weeks, indicating its potential to compete with Eli Lilly and Novo Nordisk in the obesity drug market.
- Market Share Opportunity: With a market cap of just $3.5 billion, capturing even 1% of the projected $100 billion weight-loss drug market could significantly elevate Viking's valuation, providing substantial returns for shareholders.
- Clinical Trial Progress: The phase 3 trials for the injectable formulation of VK2735 completed enrollment earlier this year, with top-line data not expected until 2027, while the oral formulation's phase 3 trial is anticipated to begin by the end of this year.
- Industry Competitive Landscape: Although VK2735 shows competitive potential in the short term, it must prove its long-term efficacy against late-stage candidates like Eli Lilly's retatrutide and Novo Nordisk's CagriSema to secure a foothold in the market.
See More
Teads and Corning See Surge in Options Trading Volume
- Teads Options Volume: Teads Holding Co experienced options trading volume of 1,934 contracts, equivalent to approximately 193,400 shares, representing about 65.3% of its average daily trading volume of 296,010 shares over the past month, indicating market interest in its future performance.
- High Strike Call Options: Specifically, the $2.50 strike call option for Teads saw 1,030 contracts traded today, representing around 103,000 underlying shares, reflecting investor expectations for the stock's upward movement before expiration on July 17, 2026.
- Corning Options Activity: Corning Inc recorded options trading volume of 82,742 contracts, translating to approximately 8.3 million shares, which is about 65.1% of its average daily trading volume of 12.7 million shares over the past month, showcasing strong market interest in its stock.
- Corning High Strike Call Options: For Corning, the $300 strike call option traded 4,704 contracts today, representing approximately 470,400 underlying shares, indicating investor optimism regarding potential price increases before the option's expiration on July 17, 2026.
See More
Amazon and Costco: Top Picks for Long-Term Investment
- Amazon's Market Advantage: Amazon (AMZN) holds a massive market share in e-commerce and cloud computing, with a market cap of $2.6 trillion, and is poised for future growth driven by its strong global network and Prime membership service amidst the AI boom.
- AWS Growth Potential: Amazon Web Services (AWS), the world's largest cloud service provider, boasts an annual revenue run rate of $150 billion, benefiting from a surge in AI projects, which further solidifies Amazon's profitability and market position.
- Costco's Business Model: Costco (COST) is renowned for its membership-based low-price strategy, with a market cap of $422 billion and a renewal rate exceeding 92% in the U.S. and Canada, providing visibility for future profits.
- Expansion Plans and Profitability: With 928 stores globally and plans to open over 30 new warehouses annually, Costco's high-margin membership fees ensure long-term profitability and competitive strength, despite low margins on product sales.
See More
